Most experts currently believe that HIV type 1 (HIV-1) protease inhibitors (PIs) and nucleoside reverse transcriptase inhibitors (NRTIs), especially stavudine and zidovudine, are implicated. (medscape.com)
One key study showed a 3,059% increase in simvastatin exposure when coadministration with the protease inhibitor combo, saquinavir (Invirase) and ritonavir (Norvir).2 The mechanism for the interaction is potent inhibition of the cytochrome P450 3A4 enzyme by all known protease inhibitors. (ebmconsult.com)
Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. (ebmconsult.com)
HA565 trade name] is indicated as a pharmacokinetic enhancer for protease inhibitors when these are used in combination therapy with other antiretroviral agents for the treatment of HIV-1 infected patients. (who.int)
As [HA565 trade name] is used as a pharmacokinetic enhancer with other protease inhibitors, the product information for the particular protease inhibitor must be consulted. (who.int)
The following HIV-1 protease inhibitors can be used with ritonavir as a pharmacokinetic enhancer at the noted doses. (who.int)
Please refer to the product information of the protease inhibitors approved for co-administration with ritonavir. (who.int)
In particular, protease inhibitors and non-nucleoside reverse transcriptase inhibitors affect the CYP450 or other transporter systems and may be associated with clinically significant drug interactions. (hiv.gov)
In drug combination studies of delavirdine with zidovudine, didanosine, zalcitabine, lamivudine, interferon-α, and protease inhibitors, additive to synergistic anti-HIV-1 activity was observed in cell culture. (drugs.com)
Inhibitor12
Praluent is the only EC-approved PCSK9 inhibitor that is available in two starting doses, offering two levels of efficacy. (europeanpharmaceuticalreview.com)
However, use of simvastatin in HIV-infected patients receiving highly active antiretroviral therapy (HAART) is limited by the potential for this drug to interact with antiretroviral medications, specifically drugs from the protease inhibitor class. (ebmconsult.com)
In particular, CYP450 3A4 is responsible for the vast majority of simvastatin metabolism and plasma clearance.3 Thus, protease inhibitor mediated inhibition of the CYP450 3A4 clearance pathway for simvastatin results in dangerously high concentrations of this statin. (ebmconsult.com)
The recommended dose is 100 mg ritonavir once or two times per day, depending on the concurrently used protease inhibitor. (who.int)
For children who are undergoing anti-tuberculosis treatment with rifampicin, higher dosages of ritonavir may be needed for pharmacokinetic enhancement of the combined protease inhibitor. (who.int)
Depending on the specific protease inhibitor with which it is co-administered, ritonavir may be appropriate for use with caution in patients with renal insufficiency. (who.int)
For specific dosing information in patients with renal impairment, refer to the product information of the co-administered protease inhibitor. (who.int)
In the absence of pharmacokinetic studies in patients with stable severe hepatic impairment (Child Pugh grade C) without decompensation, caution should be exercised when ritonavir is used as a pharmacokinetic enhancer as increased levels of the co-administered protease inhibitor may occur. (who.int)
Specific recommendations for use of ritonavir as a pharmacokinetic enhancer in patients with hepatic impairment are dependent on the protease inhibitor with which it is co-administered. (who.int)
The drug is also approved to treat patients with HCV genotype 1 infections who have been treated with a regimen containing either an NS5A inhibitor or an NS3/4A protease inhibitor, but not both. (acponline.org)
Ritonavir boosted protease inhibitor therapy was discontinued and he was placed on Raltegravir which is not known to inhibit CYP3A4. (springeropen.com)
Evaluate the Efficacy2
A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Orally Administered ALS-008176 in Adults Hospitalized with a Respiratory Syncytial Virus-Related Illness. (midwayresearch.org)
Double blind, randomised, placebo-controlled trial to evaluate the efficacy of esomeprazole to treat early onset pre-eclampsia (PIE Trial): a study protocol. (nbmrf.org.au)
Simvastatin2
One study reported that 21% of HIV infected patients were receiving a contraindicated statin with their PI.11 Therefore, the combination of simvastatin and PIs should be avoided and other statin options (such as pravastatin which does not undergo CYP450 metabolism) are preferred.12 Use of simvastatin with nevirapine, efavirenz, or etravirine may be acceptable. (ebmconsult.com)
Safety and efficacy of simvastatin for the treatment of dyslipidemia in human immunodeficiency virus-infected patients receiving efavirenz-based highly active antiretroviral therapy. (ebmconsult.com)
Enzyme1
Action Inhibits HIV protease, the enzyme required to form functional proteins in HIV-infected patients. (medicscientist.com)
Do not administer by intravenous or intramuscular injection as no data is available on the safety or efficacy via these routes. (pdr.net)
As a pioneer in the drug transporter field for 20 years, SOLVO is dedicated to exploring the science of transporters and their role in xenobiotic efficacy and safety. (solvobiotech.com)
Dyslipidemia1
Other medical conditions included coronary artery disease, dyslipidemia and GERD treated with aspirin, clopidogrel, omeprazole, pravastatin and niacin. (springeropen.com)
Proteins1
PIs also have a high affinity for the catalytic site of HIV-1 protease, which shares a 60% sequence homology with 2 proteins involved in lipid metabolism, cytoplasmic retinoic acid-binding protein type 1 (CRABP-1), and low-density lipoprotein receptor-related protein (LDLR-RP). (medscape.com)
Reduction1
With either treatment scheme, Ncx-6550 produced higher cardioprotection compared to pravastatin, as reflected also by a reduction in the incidence of lethality as well as in circulating troponin I and interleukin-1β levels. (gsk-3signals.com)
Properties2
The Cardio-Protective Properties of Ncx-6550, a Nitric Oxide Donating Pravastatin, in the Mouse. (gsk-3signals.com)
Objective: Determine the cardio-protective properties of a nitric oxide-releasing pravastatin (Ncx-6550), in comparison to pravastatin. (gsk-3signals.com)
Therapy1
The identified gene probes are useful for selecting and monitoring therapy, and for defining efficacy of novel agents in the autoimmune rheumatic diseases. (justia.com)
Human1
Effects of Pravastatin on human placenta, endothelium and women with severe preeclampsia. (nbmrf.org.au)
Products1
The products are labeled as containing pravastatin but actually contain bupropion hydrochloride extended-release tablets (300 mg). (acponline.org)
Pharmacokinetics1
14. Assessment of the Effect of Filgotinib on the Pharmacokinetics of Atorvastatin, Pravastatin, and Rosuvastatin in Healthy Adult Participants. (nih.gov)
Simeprevir1
In April 2014, Janssen announced initiation of the Phase 3 OPTIMIST trials examining the safety and efficacy of simeprevir and sofosbuvir without interferon or ribavirin for the treatment of chronic genotype 1 HCV infection. (jnj.com)
Peginterferon alfa1
OLYSIO™ efficacy has been established in combination with peginterferon alfa and ribavirin in HCV genotype 1-infected patients with compensated liver disease, including cirrhosis. (jnj.com)
Treatment1
In a study comparing efficacy and cost of treatment, both surgeons and patients assessed the results of Sculptra, Radiesse, Aquamid, or autologous fat. (medscape.com)